Linked Life Data

1627233

Source:http://linkedlifedata.com/resource/pubmed/id/1627233

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1992-8-20
pubmed:abstractText
The therapeutic effect of the ether phospholipid SRI 62-834, which lacks the characteristics of an immunosuppressive agent, was compared with those of two immunosuppressive drugs, cyclosporin and valine2-dihydrocyclosporin, in a rat model of chronic relapsing experimental allergic encephalomyelitis (CR-EAE). Drug treatment was initiated at the beginning of the first spontaneous remission on day 15 and was discontinued on day 31. Whereas the untreated rats experienced two paralytic relapses around days 21 and 31, the progression of CR-EAE was prevented during the period of drug administration. Protection with both cyclosporin and its derivative was complete, but SRI 62-834 only attenuated the clinical disease. The absence of paralytic symptoms was reflected by a distinct reduction in mononuclear cell infiltration in the central nervous system at days 21 and 31 in treated animals. The main difference between the two drug classes became apparent after withdrawal of therapy. Discontinuation of SRI 62-834 resulted in a long-lasting beneficial effect, with the rats remaining clinically normal and showing no histopathological changes. However, cyclosporin only delayed the clinical symptoms which reappeared after cessation of treatment. The exacerbated paralytic relapse, which followed about 1 week later and was associated with severe perivascular cell infiltrates and tissue destruction, subsequently became chronic in several animals. By contrast, withdrawal of valine2-dihydrocyclosporin partially prevented disease relapse and markedly reduced severity of symptoms without progression of a chronic disease. These results demonstrate the clear differences in the mode of action of these compounds in CR-EAE and suggest that SRI 62-834 could be an interesting candidate for the treatment of multiple sclerosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0896-8411
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
199-211
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:1627233-Animals, pubmed-meshheading:1627233-Cell Movement, pubmed-meshheading:1627233-Central Nervous System, pubmed-meshheading:1627233-Chronic Disease, pubmed-meshheading:1627233-Cyclosporine, pubmed-meshheading:1627233-Cyclosporins, pubmed-meshheading:1627233-Disease Models, Animal, pubmed-meshheading:1627233-Drug Evaluation, Preclinical, pubmed-meshheading:1627233-Encephalomyelitis, Autoimmune, Experimental, pubmed-meshheading:1627233-Female, pubmed-meshheading:1627233-Furans, pubmed-meshheading:1627233-Immunosuppressive Agents, pubmed-meshheading:1627233-Lymph Nodes, pubmed-meshheading:1627233-Lymphocytes, pubmed-meshheading:1627233-Multiple Sclerosis, pubmed-meshheading:1627233-Phospholipid Ethers, pubmed-meshheading:1627233-Rats, pubmed-meshheading:1627233-Rats, Inbred Lew, pubmed-meshheading:1627233-Recurrence, pubmed-meshheading:1627233-Remission Induction
pubmed:year
1992
pubmed:articleTitle
SRI 62-834, a cyclic ether analogue of the phospholipid ET-18-OCH3, displays long-lasting beneficial effect in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Comparison with cyclosporin and (Val2)-dihydrocyclosporin effects in clinical, functional and histological studies.
pubmed:affiliation
Preclinical Research, Sandoz Pharma Ltd, Basel, Switzerland.
pubmed:publicationType
Journal Article, Comparative Study